|
|
 |
|
Viewing report
|
|
|
|
Global Biosimilars (Follow-on biologics) Market: An Analysis
Koncept Analytics, Nov 2010, Pages: 36
Biosimilars or FOBs (Follow-on biologics) refer to generic versions of patented branded biological drugs, developed subsequent to the patent expiry of brand name products. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. In 2009, biosimilar recombinant non glycosylated protein products formed the largest market segment since blockbuster biopharmaceutical drug such as interferon, human growth hormone-Somatropin, insulin and G-CSF; belong to this class and have wide range of applications.
Overburdened due to rising healthcare costs, ageing population, expensive drugs and pharmaceutical expenditure, biosimilar market is getting boost from increasing user acceptance and emerging Indian and Chinese markets. The major challenge for the biosimilar market is risk involved with the high investment and possible failure of the drug during development stages. However, opportunities for biosimilar market is immense, as biologics are going to be off patent by 2015 and an anticipated approval pathway in U.S will open up potentially largest market. The growth potential of the biosimilars market is expected to be strong, with patents for a number of second-generation therapeutic proteins (Enbrel, Remicade, Herceptin, etc.) slated for expiry between 2013 and 2019. The global biosimilars market is highly fragmented with the presence of some leading players such as Biocon, Dr Reddy's Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt.
The report titled “Global Biosimilars (Follow-on biologics) Market: An Analysis” covers the overview, market size and segmentation of the biosimilars market. The various drivers and the challenges faced by the market are also discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market.
Customers who bought this item also bought
Biosimilars (2009 - 2014)
Biosimilars - Global Strategic Business Report
Biosimilars and Biobetters: Positioning for a New Market
Biosimilar Opportunities: Pipelines and Companies
Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues
Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
Global Biosimilars Industry
A Guide to Biosimilars, Biogenerics and Follow-On Biologics
Delivering New Biopharmaceutical Therapies: Challenges & Opportunities
Big Pharma’s New Licensing Strategies
|
|
|
|
